Principles in pharmacogenetics

Epilepsia

Volumn 42, Issue SUPPL. 5, 2001, Pages 44-48

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; LAMOTRIGINE; NEUROLEPTIC AGENT; PHENFORMIN; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; CONFERENCE PAPER; DRUG DISPOSITION; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0034790535     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2001.0s008.x     Document Type: Conference Paper

References (44)

1. The geneticist's approach to complex disease
2. Prolonged apnea following injection of succinylcholine
3. Genetic control of isoniazid metabolism in man
4. Polymorphisms of N-acetyl-transferase genes
5. Hypotensive response to debrisoquine and hydroxylation phenotype
6. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
7. Molecular mechanisms of genetic polymorphisms of drug metabolism
8. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
9. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects
10. Unpredictability of flecainide plasma concentrations in patients with renal failure: Relation to side effects and sudden death?
11. Ultrarapid hydroxylation of debrisoquine in a Swedish population: Analysis of the molecular genetic basis
12. Genetically variable metabolism of anti-depressants and neuroleptic drugs in man
13. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
14. Genetic polymorphism of thiopurine methyhransferase and its clinical relevance for childhood acute lymphoblastic leukemia
15. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
16. Pharmacogenomics: Translating functional genomics into rational therapeutics
17. Point of view: Acquired long QT syndromes and the risk of proarrhythmia
18. Mechanism of the cardiotoxic actions of terfenadine
19. Torsades de pointes with an antihistamine metabolite- potassium channel blockade with desmethylastemizole
20. Interaction between quinidine and digoxin
21. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P-glycoprotein
22. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
23. Absence of the mdr la P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
24. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
25. P-glycoprotein transporter limits oral absorption and brain entry of HIV protease inhibitors
26. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
27. Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis
28. Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions
29. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
30. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia
31. Positional cloning of a novel potassium channel gene: KVLQTI mutations cause cardiac arrhythmias
32. Ks function
33. Kr potassium channels with HERG and is associated with cardiac arrhythmia
34. A potassium channel mutation in neonatal human epilepsy
35. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
36. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
37. +-channel beta1 subunit gene SCN1B
38. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
39. Kr: Implications for torsades de pointes and reverse use-dependence
40. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome
41. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
42. KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels
43. Pharmacogenetics and future drug development and delivery